Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology

Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2016-04, Vol.99 (4), p.360-362
Main Authors: Oettrich, JM, Dao, VT, Frijhoff, J, Kleikers, PWM, Casas, AI, Hobbs, AJ, Schmidt, HHHW
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Pharmacological - metabolism
Cyclic GMP - metabolism
Drug Discovery - methods
Enzyme Activation
Enzyme Activators - chemistry
Enzyme Activators - pharmacology
Guanylate Cyclase - metabolism
Humans
Molecular Structure
Phosphodiesterase Inhibitors - chemistry
Phosphodiesterase Inhibitors - pharmacology
Receptors, Guanylate Cyclase-Coupled - agonists
Receptors, Guanylate Cyclase-Coupled - metabolism
Second Messenger Systems - drug effects
Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.336